Satisfaction and Awareness of Systemic Psoriasis Treatments: A National Survey Comparing Biologic and Nonbiologic Users
Satisfaction and Awareness of Systemic Psoriasis Treatments: A National Survey Comparing Biologic and Nonbiologic Users
复制标题
DOI：
10.1177/1203475418808764
复制
发表时间：
2019-03-01
影响因子：
2.3
通讯作者：
Manolson, Morris F.
中科院分区：
文献类型：
--
作者：
Ighani, Arvin;Yu, Ashley M.;Manolson, Morris F.
工作背景：目前正在开发银屑病的新疗法，包括生物和全身性药物，如白细胞介素-17、白细胞介素-23和磷酸二酯酶-4抑制剂。这些药物的发展改变了银屑病治疗选择的前景。目的：本研究的目的是描述2016年6月之前批准的新型生物制剂和全身制剂对患者结局的影响。我们试图评估和比较生物制剂使用者和非生物制剂系统使用者的治疗意识和满意度。研究方法：我们于2016年7月至9月对使用生物制剂或非生物全身性制剂作为当前主要治疗方式的中重度银屑病成人患者进行了一项全国性加拿大调查。要求患者评估他们对治疗药物的总体满意度以及对其他治疗方案的认识。比较了生物制剂和非生物制剂系统使用者的反应。结果：总体而言，纳入了343名参与者（生物制剂使用者：n = 218;非生物制剂使用者：n = 125）。治疗满意度：生物制剂使用者的总体满意度评分高于非生物制剂使用者（P <.001）。在非生物制剂中，阿普斯特（62%）的满意度最高。在生物制剂中，优特克单抗（77%）和阿达木单抗（72%）的满意度最高。在治疗意识方面，30%的非生物制剂患者没有足够的信息来形成对生物制剂的看法。结论：这项研究表明，与非生物制剂使用者相比，生物制剂使用者对中重度银屑病的治疗满意度更高。鉴于近三分之一的非生物制剂使用者没有足够的信息来形成对生物制剂的看法，医生可以考虑咨询这些患者使用生物制剂治疗银屑病。
Background: There is ongoing development of new therapies for psoriasis, including biologic and systemic agents such as interleukin-17, interleukin-23, and phosphodiesterase-4 inhibitors. The development of these agents has changed the landscape of psoriasis treatment options. Objective: The objective of this study was to characterize the impact of newer biologic and systemic agents approved by June 2016 on patient outcomes. We sought to evaluate and compare biologic users and nonbiologic systemic users with respect to their treatment awareness and satisfaction. Methods: We conducted a national Canadian survey from July to September 2016 on adult patients with moderate-to-severe psoriasis using biologic agents or nonbiologic systemic agents as their current primary treatment modality. Patients were asked to evaluate their overall satisfaction with their treatment agent and their awareness of other treatment options. Responses from biologic and nonbiologic systemic users were compared. Results: Overall, 343 participants were included (biologic users: n = 218; nonbiologic users: n = 125). Treatment satisfaction: Biologic users had a higher overall satisfaction score than nonbiologic users (P < .001). Among nonbiologic agents, apremilast (62%) was associated with the highest satisfaction proportion. Among biologic agents, ustekinumab (77%) and adalimumab (72%) were associated with the highest proportions of satisfaction. With respect to treatment awareness, 30% of nonbiologic patients did not have enough information to form an opinion about biologics. Conclusions: This study demonstrates the greater treatment satisfaction of biologic users compared with nonbiologic users for moderate-to-severe psoriasis. Given that nearly one-third of nonbiologic users did not have enough information to form an opinion about biologic agents, physicians may consider counselling these patients on the use of biologic agents for psoriasis management.